MannKind (NASDAQ:MNKD) Price Target Raised to $4.75

Key Points

• Royal Bank of Canada raised its price target on MannKind to $4.75 (about 33.5% upside), while the analyst consensus remains a "Moderate Buy" with a mean target of $8.84 (7 Buy, 2 Hold, 1 Sell).
• MannKind's Q1 results missed expectations—EPS of ($0.05) vs. ($0.02) expected and revenue of $90.17M vs. $105.38M expected—despite 15.1% YoY revenue growth, leaving thin margins and a negative ROE as near‑term concerns.
• The company announced a collaboration with United Therapeutics to develop a dry‑powder inhalation (DPI) version of ralinepag—including a $5M upfront payment, up to $35M in development milestones and 10% royalties—and CEO Michael Castagna purchased 100,000 shares at $2.59, increasing his stake.

MannKind (NASDAQ:MNKD - Get Free Report) had its target price raised by investment analysts at Royal Bank Of Canada from $3.50 to $4.75 in a research note issued on Thursday,Benzinga reports. The firm currently has a "sector perform" rating on the biopharmaceutical company's stock. Royal Bank Of Canada's price target points to a potential upside of 33.50% from the company's previous close.

Other equities research analysts have also recently issued reports about the company. Wedbush decreased their price objective on MannKind from $10.00 to $8.00 and set an "outperform" rating for the company in a research note on Thursday, March 5th. HC Wainwright upped their price objective on MannKind from $8.00 to $10.00 and gave the stock a "buy" rating in a research note on Thursday. Weiss Ratings cut MannKind from a "hold (c)" rating to a "sell (d+)" rating in a research note on Monday, March 2nd. Mizuho decreased their price target on MannKind from $8.00 to $7.00 and set an "outperform" rating for the company in a research note on Thursday. Finally, Zacks Research upgraded MannKind from a "strong sell" rating to a "hold" rating in a research note on Wednesday, April 15th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $8.84.

MannKind Stock Down 0.1%

Shares of NASDAQ MNKD traded down $0.00 during mid-day trading on Thursday, reaching $3.56. 10,154,275 shares of the company were exchanged, compared to its average volume of 5,653,637. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of 178.84 and a beta of 1.04. MannKind has a 1 year low of $2.23 and a 1 year high of $6.51. The firm has a 50-day moving average of $2.77 and a 200 day moving average of $4.60.

MannKind (NASDAQ:MNKD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.03). The company had revenue of $90.17 million for the quarter, compared to analysts' expectations of $105.38 million. MannKind had a negative return on equity of 11.21% and a net margin of 1.68%.The company's revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter last year, the company earned $0.04 earnings per share. On average, equities analysts forecast that MannKind will post -0.02 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Michael Castagna acquired 100,000 shares of the business's stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $2.59 per share, with a total value of $259,000.00. Following the completion of the acquisition, the chief executive officer owned 2,575,911 shares of the company's stock, valued at approximately $6,671,609.49. This trade represents a 4.04% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Level Four Advisory Services LLC increased its holdings in shares of MannKind by 12.5% in the third quarter. Level Four Advisory Services LLC now owns 17,333 shares of the biopharmaceutical company's stock valued at $93,000 after purchasing an additional 1,925 shares during the period. Franklin Resources Inc. increased its holdings in shares of MannKind by 1.4% in the third quarter. Franklin Resources Inc. now owns 162,217 shares of the biopharmaceutical company's stock valued at $871,000 after purchasing an additional 2,201 shares during the period. Aaron Wealth Advisors LLC increased its holdings in shares of MannKind by 1.2% in the fourth quarter. Aaron Wealth Advisors LLC now owns 200,763 shares of the biopharmaceutical company's stock valued at $1,138,000 after purchasing an additional 2,355 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of MannKind by 7.8% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 33,405 shares of the biopharmaceutical company's stock valued at $189,000 after purchasing an additional 2,404 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of MannKind by 6.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 39,234 shares of the biopharmaceutical company's stock valued at $220,000 after purchasing an additional 2,443 shares during the period. 49.55% of the stock is owned by institutional investors and hedge funds.

MannKind News Summary

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: MannKind announced a collaboration with United Therapeutics to develop a dry‑powder inhalation (DPI) version of ralinepag for pulmonary hypertension and fibrotic lung diseases; United Therapeutics made an additional $5 million payment, will be the primary manufacturer, and MannKind is eligible for up to $35 million in development milestones plus 10% royalties — a potential multi‑year revenue stream and validation of MannKind’s inhalation platform. Ralinepag DPI Program
• Positive Sentiment: Mizuho cut its price target from $8 to $7 but kept an “outperform” rating, signaling that at least some analysts still see substantial upside from current levels — this can support bullish sentiment despite the cut. Mizuho Price Target Note
• Neutral Sentiment: MannKind posted its Q1 2026 presentation, press release and hosted an earnings call — useful for investors wanting management commentary on sales drivers, margins, and commercial execution. Q1 Slide Deck / Press Release
• Neutral Sentiment: Recent coverage and analysis (including a Seeking Alpha piece titled “MannKind: It’s Complicated”) discuss the company’s mixed fundamentals and strategic options — these pieces provide additional context but are interpretive rather than new corporate actions. It's Complicated
• Negative Sentiment: Q1 results missed expectations: EPS of ($0.05) vs. consensus ($0.02) and revenue of $90.17M vs. $105.38M expected; while revenue rose year‑over‑year, the shortfall and a low net margin/negative ROE raise near‑term execution and profitability concerns. Q1 Miss / Zacks

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company's core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind's lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.